AECOM
F:E6Z
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AECOM
F:E6Z
|
US |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
US |
|
B
|
BP PLC
XMUN:BPE5
|
UK |
|
A
|
ArcelorMittal SA
SWB:ARRD
|
LU |
|
Fresenius Medical Care AG & Co KGaA
NYSE:FMS
|
DE |
|
A
|
Assicurazioni Generali SpA
XMUN:ASG
|
IT |
|
Crane Co
F:T12
|
US |
|
H
|
Hyundai Motor Co
KRX:005387
|
KR |
|
R
|
Rambus Inc
XMUN:RMB
|
US |
|
R
|
Rhoen Klinikum AG
XMUN:RHK
|
DE |
Wall St Price Targets
E6Z Price Targets Summary
AECOM
According to Wall Street analysts, the average 1-year price target for E6Z is 175.49 EUR with a low forecast of 145.66 EUR and a high forecast of 243.98 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is E6Z's stock price target?
Price Target
175.49
EUR
According to Wall Street analysts, the average 1-year price target for E6Z is 175.49 EUR with a low forecast of 145.66 EUR and a high forecast of 243.98 EUR.
What is the Revenue forecast for AECOM?
Projected CAGR
-13%
Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 3 years is -13%.
What is the Gross Profit forecast for AECOM?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 2 years is 8%.
What is the Operating Income forecast for AECOM?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Operating Income has been 9%. The projected CAGR for the next 3 years is 11%.
What is the Pre-Tax Income forecast for AECOM?
Projected CAGR
13%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 36%. The projected CAGR for the next 3 years is 13%.
What is the Net Income forecast for AECOM?
Projected CAGR
19%
The compound annual growth rate for Net Income over the next 3 years is 19%.
